GLP1 receptor agonists are widely prescribed to help control blood sugar levels and support weight loss. While these ...

Applause, the world leader in digital quality and crowd-sourced testing, today announced another milestone year, surpassing $200 million in Annual Recurring Revenue (ARR). Building on its unparalleled ...

KYOCERA AVX, a leading global manufacturer of advanced electronic components engineered to accelerate technological ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Previous studies suggest GLP-1 receptor agonists may benefit those with Parkinson’s disease. A phase 3 randomized controlled trial found no significant improvements with the GLP-1 exenatide in ...

Director, Insights & Innovation at youtheory®. "Our new line of doctor-formulated GLP-1 Support supplements is designed to fill those gaps and help users stay nourished, energized, and confident ...